Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus Price Target from Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has earned a consensus recommendation of “Buy” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.50.

IPSC has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Piper Sandler dropped their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd.

Century Therapeutics Price Performance

NASDAQ:IPSC opened at $0.58 on Thursday. The firm has a market cap of $49.57 million, a PE ratio of -0.32 and a beta of 1.75. The company has a 50-day moving average of $0.76 and a 200 day moving average of $1.17. Century Therapeutics has a 1-year low of $0.55 and a 1-year high of $5.24.

Institutional Trading of Century Therapeutics

Institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC boosted its stake in Century Therapeutics by 56.0% in the fourth quarter. Squarepoint Ops LLC now owns 164,871 shares of the company’s stock valued at $167,000 after acquiring an additional 59,174 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Century Therapeutics in the 4th quarter worth $67,000. Two Sigma Advisers LP acquired a new stake in shares of Century Therapeutics in the 4th quarter worth $52,000. Nuveen Asset Management LLC boosted its position in shares of Century Therapeutics by 48.9% in the 4th quarter. Nuveen Asset Management LLC now owns 157,311 shares of the company’s stock worth $159,000 after purchasing an additional 51,661 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Century Therapeutics by 1,041.8% in the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock worth $1,623,000 after purchasing an additional 1,466,415 shares in the last quarter. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.